Clinical Trials Browser

Phase 1/2 × Uterine Cervical Neoplasms × nimotuzumab × Clear all

NCT02095119 2015-04-14

A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer

Phase 1/2 Completed

Uterine Cervical Neoplasms